source
- Bristol Myers' lung drug admilparant meets Phase 3 goal at low dose, high dose falls shortBristol Myers Squibb reported that its experimental idiopathic pulmonary fibrosis therapy admilparant achieved its primary endpoint in a Phase 3 trial, showing a statistically significant slowing o…
- First Tracks reports positive early-stage results for celiac drug ANB033First Tracks Biotherapeutics announced that its experimental celiac disease drug ANB033 showed statistically significant improvement in a six‑week early‑stage trial compared with placebo. The trial…